Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Teva Pharmaceutical Industries ADR (NY: TEVA ) 16.82 +0.21 (+1.26%) Official Closing Price Updated: 7:00 PM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Teva Pharmaceutical Industries ADR < Previous 1 2 3 4 5 6 7 Next > Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) June 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 June 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire 2 Generic Drug Makers With Growing Runways May 31, 2024 Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Via MarketBeat Topics Intellectual Property Exposures Intellectual Property Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) May 29, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. May 20, 2024 From Alvotech Via GlobeNewswire Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations May 15, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire These 7 Stocks Surged Double-Digits and Have Double-Digits to Go May 10, 2024 Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results. Via MarketBeat Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook May 08, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia May 08, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva to Present at the 2024 Bank of America Healthcare Conference May 02, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets May 02, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Alvotech Via GlobeNewswire Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 April 09, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 April 06, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate April 04, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement April 01, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China February 26, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire 6 reasons to buy Teva Pharmaceuticals stock sooner than later February 26, 2024 Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why Via MarketBeat Topics Lawsuit Exposures Financial Legal Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® February 23, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® February 23, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting February 20, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Reports Growth in Fourth Quarter and Full Year 2023 January 31, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy January 31, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.